Flagship Biosciences named Tom Turi, PhD, as its chief scientific officer Tuesday morning.
The spatial biology and biomarker services company said Turi will be tasked with overseeing the integration and implementation of new genomic technologies obtained through Flagship’s recent acquisition of Interpace Pharma Solutions.
Turi most recently served as chief scientific officer at Nexelis, with prior leadership stints at Labcorp Drug Development and Pfizer.
“We are very excited to have Tom join the team. He will be essential in driving our scientific strategy along with growing our scientific leadership and expertise,” Flagship Biosciences CEO Trevor Johnson said in a statement. “Tom will help to ensure that we are providing our clients with the right solutions to maximize their success in every project.”